{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T18:10:35Z","timestamp":1788977435224,"version":"build-2803163510"},"reference-count":0,"publisher":"The Medical Letter, Inc.","issue":"1763","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Lett Drugs Ther"],"abstract":"<jats:p>The FDA has licensed mFLUSIVA (Moderna), the first mRNA-based influenza vaccine in the US, for prevention of influenza in adults \u226550 years old. mFLUSIVA will be available for the 2026-2027 influenza season. Three mRNA COVID-19 vaccines (Comirnaty, Spikevax, and mNEXSPIKE) and one mRNA RSV vaccine (mRESVIA) are also licensed in the US.<\/jats:p>","DOI":"10.58347\/tml.2026.1763b","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T17:57:17Z","timestamp":1788976637000},"page":"150-151","source":"Crossref","is-referenced-by-count":0,"title":["mFLUSIVA \u2014 An mRNA-Based Influenza Vaccine"],"prefix":"10.58347","volume":"68","member":"37151","published-online":{"date-parts":[[2026,9,14]]},"container-title":["The Medical Letter on Drugs and Therapeutics"],"original-title":[],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T17:57:17Z","timestamp":1788976637000},"score":1,"resource":{"primary":{"URL":"https:\/\/secure.medicalletter.org\/TML-article-1763b"}},"subtitle":[],"editor":[{"name":"Editors from The Medical Letter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":0,"journal-issue":{"issue":"1763","published-online":{"date-parts":[[2026,9,14]]}},"URL":"https:\/\/doi.org\/10.58347\/tml.2026.1763b","relation":{},"ISSN":["1523-2859"],"issn-type":[{"value":"1523-2859","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]}}}